The Pediatric Praziquantel Consortium aims at improving the health of preschool-aged children.
The Pediatric Praziquantel Consortium aims at improving the health of preschool-aged children. Millions of preschoolaged children affected by schistosomiasis are not receiving treatment due to the lack of a suitable medicine. To address this unmet need, the Pediatric Praziquantel Consortium has developed a potential new treatment option that has now been validated for review by the European Medicines Agency. This is a key milestone in the ongoing effort to eliminate this neglected tropical disease. As a member of the consortium, Swiss TPH conducted the clinical trials. Today, the Pediatric Praziquantel Consortium announced that the European Medicines Agency (EMA) has validated for review the application for its potential new child-friendly drug for the treatment of schistosomiasis in preschool-aged children (3 months to 6 years of age). With this validation, the regulatory application for the pediatric drug is complete and EMA will now begin the scientific review process.
TO READ THIS ARTICLE, CREATE YOUR ACCOUNT
And extend your reading, free of charge and with no commitment.
